Last May, over 275 delegates participated at the 7th Annual World Stem Cells & Regenerative Medicine Congress in London. The congress brings together the late stage cell therapy developers, key opinion leaders, senior regenerative medicine stakeholders and the most innovative stem cell researchers to share expertise and discuss what it takes to achieve successful clinical development and commercialise a cellular therapy with up-scale manufacture. Topics debated include pricing and market access, accelerating cell therapy clinical development and achieving regulatory approval.
Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Ludovic Vallier, Senior Non-clinical MRC Fellow, Reader in Stem Cells & Regenerative Medicine, University of Cambridge. This presentation covers the following key points:
- Large scale derivation of hIPSC is feasible
- A wide diversity of endoderm cells can be generated in vitro
- Artificial DE derivatives are similar to their natural counterpart
- Protocol works with a broad number of patients > 60%
- Variability between hIPSC lines is not provoked by differences between age, gender, method of reprogramming
- Variability between hIPSCs is influence by genetic background of hIPSC and thus could be representative of human genetic diversity
Dr. Vallier will be returning to speak at next months 8th Annual World Stem Cells & Regenerative Medicine Congress 2013 taking place in London on the 21st-23rd May.
With only 3 weeks until the event, final delegate places are available so book now to ensure your seat at the table at this year's meeting. You can download the brochure here to view the full 2013 agenda.